Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.


Creative Commons License

Fizazi K., Shore N., Tammela T. L. , Ulys A., Vjaters E., Polyakov S., ...Daha Fazla

The New England journal of medicine, cilt.380, ss.1235-1246, 2019 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 380
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1056/nejmoa1815671
  • Dergi Adı: The New England journal of medicine
  • Sayfa Sayıları: ss.1235-1246

Özet

BACKGROUND

Darolutamide is a structurally unique androgen-receptor antagonist that is under de- velopment for the treatment of prostate cancer. We evaluated the efficacy of darolu- tamide for delaying metastasis and death in men with nonmetastatic, castration- resistant prostate cancer.

METHODS

We conducted a randomized, double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic, castration-resistant prostate cancer and a prostate-specific antigen doubling time of 10 months or less. Patients were randomly assigned in a 2:1 ratio to receive darolutamide (600 mg [two 300-mg tablets] twice daily) or placebo while continuing androgen-deprivation therapy. The primary end point was metas- tasis-free survival, with the presence of metastasis determined by independent cen- tral review of radiographic imaging every 16 weeks.

RESULTS

In total, 1509 patients underwent randomization (955 to the darolutamide group and 554 to the placebo group). In the planned primary analysis, which was performed after 437 primary end-point events had occurred, the median metastasis-free survival was 40.4 months with darolutamide, as compared with 18.4 months with placebo (hazard ratio for metastasis or death in the darolutamide group, 0.41; 95% confidence interval, 0.34 to 0.50; P<0.001). Darolutamide was also associated with benefits with regard to all secondary end points, including overall survival, time to pain progres- sion, time to cytotoxic chemotherapy, and time to a symptomatic skeletal event. The incidence of adverse events that occurred or worsened during the treatment period and had a frequency of 5% or more or were of grade 3 or higher was similar in the two groups; all such events except fatigue occurred in less than 10% of patients in either group. The percentage of patients who discontinued the assigned regimen because of adverse events was 8.9% in the darolutamide group and 8.7% in the placebo group. Darolutamide was not associated with a higher incidence of seizures, falls, fractures, cognitive disorder, or hypertension than placebo.

CONCLUSIONS

Among men with nonmetastatic, castration-resistant prostate cancer, metastasis-free survival was significantly longer with darolutamide than with placebo. The incidence of adverse events was similar for darolutamide and placebo. (Funded by Bayer HealthCare and Orion Pharma; ARAMIS ClinicalTrials.gov number, NCT02200614.)